NextCure (NASDAQ:NXTC) Announces Quarterly Earnings Results

NextCure (NASDAQ:NXTC) issued its quarterly earnings data on Thursday. The company reported ($1.87) earnings per share for the quarter, missing the consensus estimate of ($1.85) by ($0.02), FiscalAI reports.

NextCure Price Performance

Shares of NASDAQ NXTC traded down $0.54 during mid-day trading on Thursday, reaching $10.18. 13,794 shares of the company’s stock were exchanged, compared to its average volume of 44,831. The firm has a market capitalization of $36.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.43. NextCure has a 52 week low of $4.44 and a 52 week high of $15.74. The firm has a 50-day moving average price of $11.31 and a two-hundred day moving average price of $11.67.

Institutional Investors Weigh In On NextCure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Ikarian Capital LLC bought a new stake in NextCure in the 4th quarter valued at about $3,382,000. Squadron Capital Management LLC bought a new stake in NextCure in the 4th quarter valued at about $3,363,000. Exome Asset Management LLC bought a new stake in NextCure in the 4th quarter valued at about $2,341,000. AWM Investment Company Inc. bought a new stake in NextCure in the 4th quarter valued at about $1,665,000. Finally, Cable Car Capital LP raised its stake in NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. 42.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.